Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
Dopamine receptor partial agonists (DRPAs; aripiprazole, brexpiprazole, and cariprazine) constitute a novel class of antipsychotics. Although they share a similar mechanism of action, DRPAs differ in their pharmacodynamics, pharmacokinetics, drug interactions, or safety and tolerability. The antipsy...
Main Authors: | Pavel Mohr, Jirí Masopust, Miloslav Kopeček |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-01-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2021.781946/full |
Similar Items
-
Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole
by: Tetsuro Kikuchi, et al.
Published: (2021-06-01) -
The pharmacogenetics of the new-generation antipsychotics – A scoping review focused on patients with severe psychiatric disorders
by: Octavian Vasiliu
Published: (2023-02-01) -
Post‐hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long‐term study (Secondary Publication)
by: Jun Ishigooka, et al.
Published: (2020-06-01) -
Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?
by: Octavian Vasiliu
Published: (2022-11-01) -
Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5‐HT2A receptors in rats
by: Naoki Amada, et al.
Published: (2019-12-01)